04-15-2019 10:01 PM CET - Business, Economy, Finances, Banking & Insurance
Print

Comprehensive Analysis on Breast Cancer Therapy Market Size with Key Players: AstraZeneca, Bayer AG, Danaher, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Novartis AG, Novocure, Pfizer Inc., and F. Hoffmann-La Roche AG

Press release from: marketstudyreport.com
PR Agency: marketstudyreport

The ‘Breast Cancer Therapy market’ research report framed by Market Study Report, LLC, delivers a thorough analysis of the industry trends influencing the global business scenario. In addition, the report offers definitive information pertaining to the commercialization aspects, revenue estimation, and market size of the industry. The report overtly defines the status of key players in the competitive landscape while including their portfolio and geographical expansion endeavors.

The Global Breast Cancer Therapy Market is anticipated to reach USD 29.6 Billion by 2026 according to a new research. In 2017, the targeted therapy segment dominated the global market, in terms of revenue.

Request a sample of this premium report at: www.marketstudyreport.com/request-a-sample/1695276/?utm_s...

Breast cancer is a disorder which is observed as malignant cell growth in the breast area. Such cancer can start at the breast tissue, ducts, or the lobules. In general, cancers developing from lobules are known as lobular carcinomas while cancer developing from the ducts are known as ductal carcinomas. The symptoms of cancer include dimpling of the skin, lumps, alteration in the breast size and impeding of fluid coming from breast. Generally, breast cancer is observed as the common disease in women over the age of 50. Moreover, the breast cancer is second most common disorder among all cancer types. This disease can be diagnosed and controlled by imaging test, physical tests, biopsy and appropriate care.

The global breast cancer therapies market is majorly driven by increasing occurrence of breast cancer cases across the globe. Rising number of breast cancer cases are related with early menarche, protracted exposure to endogenous estrogens, late menopause and late stage at first childbirth which all are anticipated to render high impact on the market growth. In addition, launch of several screening and diagnostic programs and increasing advancement in technology are other factors expected to make a remarkable growth in the market. Moreover, increasing occurrence of obesity in women after menopause, increasing consciousness regarding breast cancer, and lifestyle risk factors (alcohol consumption and smoking) are other circumstances expected to drive the growth in global breast cancer therapies market.

Request a discount on standard prices of this premium report at: www.marketstudyreport.com/check-for-discount/1695276/?utm...

Geographically, North America accounted for the largest share in the global breast cancer therapies market in 2017. The dominance is majorly owing to the increasing R&D funding through private and public organizations along with growing prevalence of breast cancer in the region. Moreover, increasing geriatric population majorly in U.S. and, breast feeding termination at an early stage are factors stimulating the risk factors for breast cancer development which in turn is expected to support the growth of breast cancer therapies market in North America region. Asia Pacific breast cancer therapies market is expected to grow at significant rate during the forecast period due to increasing occurrence of disease coupled with increasing rate of lifestyle changes and health risks associated with it. Moreover, increasing adoption of technology, refining economic settings, and rising awareness regarding disease preventions are other factors boosting the breast cancer therapies market growth across Asia Pacific region.

The leading companies profiled in the Breast Cancer Therapies Market report include AstraZeneca, Bayer AG, Danaher, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Novartis AG, Novocure, Pfizer Inc., and F. Hoffmann-La Roche AG.

Table of Contents

1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-away
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Breast Cancer Therapies Market Insights
3.1. Breast Cancer Therapies ? Industry snapshot
3.2. Breast Cancer Therapies - Ecosystem analysis
3.3. Breast Cancer Therapies Market Dynamics
3.3.1. Breast Cancer Therapies ? Market Forces
3.3.1.1. Breast Cancer Therapies Market Driver Analysis
3.3.1.2. Breast Cancer Therapies Market Restraint/Challenges analysis
3.3.1.3. Breast Cancer Therapies Market Opportunity Analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Breast Cancer Therapies Market PEST Analysis, 2017
3.6. Breast Cancer Therapies Market Value Chain Analysis
3.7. Breast Cancer Therapies Industry Trends
3.8. Competitive Ranking Analysis
4. Breast Cancer Therapies Market Size and Forecast, 2017-2026 by Therapy type
4.1. Key Findings
4.2. Targeted therapy
4.3. Chemotherapy
4.4. Surgery & radiation therapy
4.5. Hormonal therapy
5. Breast Cancer Therapies Market Size and Forecast, 2017-2026 by Region
5.1. Key Findings
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.3.1. Germany
5.3.2. UK
5.3.3. France
5.4. Asia-Pacific
5.4.1. China
5.4.2. India
5.4.3. Japan
5.5. Latin America
5.5.1. Brazil
5.6. Middle East & Africa
6. Company Profiles
6.1. AstraZeneca, Bayer AG
6.1.1. Overview
6.1.2. Financials
6.1.3. Product Benchmarking
6.1.4. Recent Developments
6.2. Danaher
6.2.1. Overview
6.2.2. Financials
6.2.3. Product Benchmarking
6.2.4. Recent Developments
6.3. Bristol Myers Squibb
6.3.1. Overview
6.3.2. Financials
6.3.3. Product Benchmarking
6.3.4. Recent Developments
6.4. Eisai Co., Ltd.
6.4.1. Overview
6.4.2. Financials
6.4.3. Product Benchmarking
6.4.4. Recent Developments
6.5. Merck & Co.
6.5.1. Overview
6.5.2. Financials
6.5.3. Product Benchmarking
6.5.4. Recent Developments
6.6. Novartis AG
6.6.1. Overview
6.6.2. Financials
6.6.3. Product Benchmarking
6.6.4. Recent Developments
6.7. Novocure
6.7.1. Overview
6.7.2. Financials

More Details on this Report: www.marketstudyreport.com/reports/breast-cancer-therapy-m...

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:

Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: www.marketstudyreport.com
Blog: www.marketstudyreport.com/blog

This release was published on openPR.
News-ID: 1703939 • Views: 497
More releasesMore releases

You can edit or delete your press release here: